CNIPA.AI

Company patentsCompare

HEAD TO HEAD

Eli LillyPfizer

Technology portfolios compared in the same window and counting units. Scale is compared only within the same field or subclass.

Same window · published 2025-01-01 — 2025-12-31Some name or date coverage is incomplete; affected counts are lower bounds

This is a structural comparison of collected portfolios. The same requested window does not establish equal entity scope, covered months or industry; no competitive ranking is inferred.

Applicant-name coverage differs. The counts below cover only the listed names and do not represent complete company portfolios.

Eli Lilly: Applicant names included in these statistics — ELI LILLY AND CO · ELI LILLY AND COMPANY USA · LILLY CO ELIReviewed names not covered — ELI LILLY AND COMPANY

Pfizer: Applicant names included in these statistics — PFIZER · PFIZER INCReviewed names not covered — PFIZER INC.

Publications
1,602
Invention share
45%
Concentration
0.73
Green technology
—
Publications
998
Invention share
47%
Concentration
0.99
Green technology
—
0.97Field similarity
Cosine similarity of application counts across 35 fields. 1 is identical, 0 is no overlap.

01Technology field mirror

The 12 fields with the largest combined share. Share shows structure; count shows scale.

Technology field mirror
Eli LillyTechnology fieldPfizer
68.5%
Pharmaceuticals
86.9%
39.9%
Biotechnology
33.8%
25.8%
Organic fine chemistry
34.9%
17.6%
Medical technology
4.2%
1.7%
Analysis of biological materials
1.1%
1.4%
Chemical engineering
1.3%
1%
Measurement
0.6%
0.6%
Computer technology
1%
0.1%
Macromolecular chemistry, polymers
1%
0.2%
Handling
0.4%
0.6%
Control
0%
0.3%
Other special machines
0.1%

Inspect one technology field

Inspect collected applications, portfolio share and supporting publications within one field. A technology overlap does not establish that companies in different industries are direct competitors.

One application may belong to multiple fields, so shares can sum to more than 100%. Drill-down lists publications; an application publication and its grant may appear separately.

02Same problem: shared IPC subclasses

The 10 subclasses in every company's top 60 with the most combined applications. Scale is compared within a subclass, never across different business scopes.

A61K
Eli Lilly926
Pfizer763
A61P
Eli Lilly766
Pfizer644
C07K
Eli Lilly454
Pfizer262
C07DHeterocyclic compounds
Eli Lilly300
Pfizer317
C12NMicroorganisms, enzymes
Eli Lilly153
Pfizer92
A61M
Eli Lilly196
Pfizer13
C07C
Eli Lilly34
Pfizer14
G01NAnalysing materials
Eli Lilly32
Pfizer16
G16H
Eli Lilly36
Pfizer11
C07H
Eli Lilly34
Pfizer8

03Where each one leans

Observed emphasis within each company’s collected top-60 IPC subclasses. A dash for another company means outside its top-60 list, not zero applications or a market gap. Incomplete coverage can also change the ordering.

Eli Lilly

  • A61M
    Eli Lilly
    196
    Pfizer
    13
  • C07K
    Eli Lilly
    454
    Pfizer
    262
  • A61BMedical diagnosis
    Eli Lilly
    36
    Pfizer
    3
  • C07J
    Eli Lilly
    23
    Pfizer
    —
  • C07H
    Eli Lilly
    34
    Pfizer
    8
  • G16H
    Eli Lilly
    36
    Pfizer
    11

Pfizer

  • A61K
    Eli Lilly
    926
    Pfizer
    763
  • A61P
    Eli Lilly
    766
    Pfizer
    644
  • C07DHeterocyclic compounds
    Eli Lilly
    300
    Pfizer
    317
  • C12P
    Eli Lilly
    14
    Pfizer
    23
  • C12QBiochemical testing
    Eli Lilly
    12
    Pfizer
    17
  • C08B
    Eli Lilly
    —
    Pfizer
    9

04Publication rhythm

Eli LillyPfizerPublications per period
Publications per period
PeriodEli LillyPfizer
2025-01≥118 (partial coverage)≥72 (partial coverage)
2025-02≥121 (partial coverage)≥83 (partial coverage)
2025-03≥158 (partial coverage)≥155 (partial coverage)
2025-04≥110 (partial coverage)≥83 (partial coverage)
2025-05≥134 (partial coverage)≥95 (partial coverage)
2025-06≥140 (partial coverage)≥78 (partial coverage)
2025-07≥138 (partial coverage)≥91 (partial coverage)
2025-08≥134 (partial coverage)≥53 (partial coverage)
2025-09≥132 (partial coverage)≥63 (partial coverage)
2025-10≥155 (partial coverage)≥92 (partial coverage)
2025-11≥140 (partial coverage)≥70 (partial coverage)
2025-12≥122 (partial coverage)≥63 (partial coverage)

Empty dashed outlines mark uncollected periods. Hatched bars and ≥ counts mark partial coverage.

Publication timing follows examination and publication cycles, not R&D intensity.

What makes it comparableThe same publication window and counting units. Companies with different windows are not put in one comparison.

What is not comparableGroup totals. Business and entity scopes differ; compare scale within a field or subclass.

Not a rankingSimilarity and shares describe structure, not patent value, quality or technical leadership.